Targetable Pathways in Advanced Bladder Cancer: FGFR Signaling

SIMPLE SUMMARY: Around 20% of advanced bladder cancer patients carry unfavorable genetic alterations in the fibroblast growth factor receptor 3 (FGFR3) gene. This review summarizes recent findings from published research and clinical trial data focusing on developing and testing therapeutics that in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jin-Fen, Caliri, Andrew W., Duex, Jason E., Theodorescu, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507635/
https://www.ncbi.nlm.nih.gov/pubmed/34638374
http://dx.doi.org/10.3390/cancers13194891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507635/
https://www.ncbi.nlm.nih.gov/pubmed/34638374
http://dx.doi.org/10.3390/cancers13194891

Ejemplares similares